Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...

InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ...

MUSC researchers are tackling MASH, or metabolic dysfunction-associated steatohepatitis, a liver disease affecting hundreds ...

Patterns of molecular activity in the blood may hold clues not only to how fit someone is, but also to the biological ...

New blood tests measuring p-tau217 levels show promise for predicting Alzheimer's risk years before symptoms appear, though ...

Discusses BGE-102 Clinical Results and Development Strategy for Cardiovascular and Retinal Disease May 8, 2026 12:30 PM ...

Izicopan is an investigational next-generation oral C5aR1 inhibitor designed to achieve differentiated pharmacological properties, with the potential for improved efficacy and safety. The marketed ...

When this is done well, biomarkers accelerate decision-making, reduce uncertainty, and ultimately bring improved therapies to patients faster. When this is done poorly, however, biomarkers can add ...

Rohde & Schwarz has announced new signal simulation capabilities supporting Pulsar, the next-generation satellite navigation ...

InflaRx intends to develop izicopan in ANCA-associated vasculitis (AAV), with a secondary goal of establishing rapid proof of concept in ...

A pilot trial is enrolling patients to test whether vagus nerve stimulation can safely promote remyelination in adults with ...